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CASE HISTORY
PK was diagnosed with autism spectrum disorder (ASD) at age
4 with the Autism Diagnostic Observation Schedule. The diagnosis was made by an interdisciplinary team consisting of
a child psychiatrist, neuropsychologist, pediatrician, and
speech/language pathologist. PK was born full term with no
complications. He demonstrated no delays in motor or language development. After the ASD diagnosis, he qualified
for no services in school except help with socialization; he
mainly had one or two friends during primary and secondary
education. Growing up, PK was articulate and performed
well in school, and he took special interest in computers. By
the onset of symptoms described below, he was 20 years
old, living at home with his mother and father, and attaining
straight As in his college computer science classes. His only
psychiatric diagnosis was ASD. There is no known family
psychiatric history. He had no prior hospitalizations and no
history of suicide attempts or self-injury. He was on no psychiatric medications. His only identified medical condition
was hypothyroidism, for which he was taking levothyroxine.
PK’s presentation began in October of 2018. His computer
science professor, who was a family friend, noticed PK’s increasing absences in the small class. When PK did come to class, he
barely spoke, and he could no longer complete his classwork
or his homework. Out of concern his professor reached out to
PK’s family.
PK then revealed to his mother that sometimes he drove to
school and simply sat in his car for eight hours before returning
home. His mother, who is a physician, also noticed other uncharacteristic behaviors. He began to eat less; initially, he skipped
perhaps one meal each day, but between October 2018 and
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January 2019, this developed into a constant refusal to eat.
During this time, PK made references that he could “see”
nanotechnology; for example, although a toaster toasts bread,
he could visualize the underlying mechanics. He also began to
move less, and when he did move, his movements became less
fluid and appeared mechanical.
In January of 2019, campus police found PK sitting alone
in his car. He had vomited and urinated on himself. He could
not tell them any identifying information, date, or time; emergency medical services subsequently admitted him to a local
hospital. At that hospital catatonia syndrome was identified,
but the team was unable initially to determine the etiology.
At presentation, his Bush-Francis Catatonia Rating Scale
(BFCRS) was 18; further detailed records are unavailable.
He was initiated on lorazepam titrated to 1 mg three times
daily (TID) while the local hospital conducted workup for
inflammatory, infectious, neoplastic, or psychiatric causes of
catatonia. Magnetic resonance imaging of the brain was negative, as was computerized tomography of the chest/abdomen/
pelvis, and scrotal ultrasound. Electroencephalogram did not
detect epileptiform activity, and lumbar puncture with cerebrospinal fluid analysis was unremarkable, including a negative
autoimmune/paraneoplastic panel. The following antibodies
were not detected: anti-thyroglobulin, antinuclear, human
immunodeficiency virus, rheumatoid factor, rapid plasma reagin, and anti-neutrophil cytoplasm. Extractable nuclear antigen (ENA10) was also negative. Complete blood count,
complete metabolic panel, liver function tests, lipid profile,
and hemoglobin A1c were within normal limits. Thyroidstimulating hormone was slightly elevated, but reflex-free T4
was within normal limits. Based on these results, the team
was unable to identify a cause for PK’s catatonia. After 12 days,
the team felt catatonia had responded adequately to lorazepam
1 mg TID and that PK was stable enough to warrant discharge
to our outpatient clinic.
PK’s parents picked him up from the local hospital. But
within 30 minutes of the car ride, it was clear that PK was
not well. He suddenly began to pull his mother’s hair, and
his father was unable to intervene. This development was
even more alarming as PK had never been aggressive before.
www.harvardreviewofpsychiatry.org

Copyright © 2022 President and Fellows of Harvard College. Unauthorized reproduction of this article is prohibited.

261

M. Gautam et al.

PK’s mother contacted us at this time, and we made immediate arrangements to transfer PK to another facility, which offered the use of their electroconvulsive therapy (ECT) capability, as we suspected it may be needed.
At this second facility, the team felt that his symptoms were
better explained by major depressive disorder and aggression
due to ASD. PK’s lorazepam was increased from 1 mg TID to
2 mg TID for aggression, and risperidone 0.5 mg twice daily
was added. He was initiated on escitalopram 10 mg for depression and discharged ten days after presentation.
We first encountered PK at our outpatient clinic in February
2019. His BFCRS was 22 on lorazepam 2 mg TID, which we
noted was an increase compared to the previously documented
score of 18. The most prominent symptoms we observed were
displays of automatic obedience, waxy flexibility, and negativism. To target worsening catatonia, we increased lorazepam to
3 mg TID. We also took note of his psychotic symptoms and
diagnosed schizophreniform disorder. As the catatonia symptoms were markedly severe compared to the psychotic symptoms, we targeted our initial treatment to improve catatonia.
As risperidone may have exacerbated catatonia, we discontinued it. We also tried to arrange outpatient ECT, but he
was declined by the performing physician because of the
potential risks.
Finally, as we were unable to corroborate the diagnosis of
major depressive disorder, we also discontinued escitalopram.
PK’s catatonia syndrome responded to slow titration of
lorazepam. By the time he was taking 5 mg lorazepam TID,
his BFCRS was 8; most prominent was waxy flexibility. With
lorazepam 6 mg TID, BFCRS was further reduced to 6, and
waxy flexibility had not yet improved. Throughout February
of 2019, as catatonia improved, his psychotic symptoms became increasingly apparent. He spoke more about nanotechnology but frequently bounced between topics, unable to describe
his thoughts linearly—which was extremely incongruous
with his previously articulate speech. He was observed many
times sitting alone in his room, having an extensive discussion
with “Lucy.” Eventually, he threw a toaster at his father because his internal discussant commanded him to do so.
In response to these developments, we advised his mother
to utilize olanzapine 2.5 mg orally disintegrating tablets as
needed for aggressive behaviors having the potential to harm
self or others. The olanzapine was slowly titrated to 5 mg
nightly for psychotic symptoms.
We selected olanzapine rather than a different antipsychotic for several reasons. Risperidone appeared to have exacerbated catatonia, which would also be a concern with
other potent D2 antagonists. Even a less potent D2 antagonist
such as aripiprazole posed a risk of exacerbating excitatory
catatonia features through akathisia. We also did not favor
quetiapine, as its antipsychotic properties typically require
high doses and prolonged titration.
As catatonia failed to lyse with lower doses of lorazepam,
we increased it to 7 mg TID. This dose of lorazepam is quite
high for the outpatient setting; however, as his mother is a
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physician, she regularly monitored his blood pressure and
also monitored for adverse events.
Olanzapine did not appear to exacerbate catatonia, but he
did refuse some doses of lorazepam. His mother did not notice
any symptoms of benzodiazepine withdrawal, but in March
2019, the BFCRS increased to 10 (emergence of mitgehen-3).
Thus, lorazepam was increased to 8 mg TID, and olanzapine
to 7.5 mg nightly.
In late March 2019, the catatonia symptoms fully resolved
(BFCRS 0), but he continued to demonstrate psychotic symptoms. Olanzapine was increased to 10 mg nightly, and lorazepam was continued at 6 mg TID. He tolerated olanzapine at
this dose and continued to display resolution of catatonia.
Olanzapine was then increased to 15 mg nightly for two
weeks and then to 20 mg to target psychotic symptoms. However, he continued to report the voice of “Lucy” and seeing
nanotechnology. His speech continued to lack its previously
articulate composition; instead, it was more reflective of
frankly disorganized thoughts.
After six weeks of olanzapine pharmacotherapy, the last of
which was at 20 mg, PK’s psychotic symptoms still did not respond. We needed to utilize an alternative agent. Now that catatonia symptoms were better controlled, we cross-titrated to a
more potent D2 antagonist by re-selecting risperidone.
As of June 2019, the psychotic symptoms had lasted for longer than six months, and his diagnosis was updated to schizophrenia. By this point, three months of risperidone pharmacotherapy at 4 mg resulted in minimal, if any, improvements in
psychotic symptoms. At a dose above 4 mg, PK began to report
intolerable dystonia-like symptoms. Because of an absence of
response to lower doses of risperidone, we believed that further
escalating the dose would most likely only expose PK to side
effects. As he now “failed” two antipsychotics (olanzapine
and risperidone), we planned a cross-titration with clozapine.
We initiated clozapine at 25 mg for three days, then increased
to 50 mg for 3 days. On day 7 we increased clozapine to 75 mg
for three days and then to 100 mg. On day 13 we increased clozapine to 150 mg for three 3 days, with the plan to increase it to
200 mg on day 16. On day 15, however, PK told his mother that
his chest hurt; his mother also took note of a slight fever and
tachycardia. Due to concern for myocarditis, his mother immediately took PK to the emergency department. Initial laboratory
work was significant for elevated troponin greater than twice
the normal limit and also for elevated C-reactive protein. As this
constellation of symptoms indicated myocarditis, clozapine was
discontinued, and PK underwent an echocardiogram.
Fortunately, echocardiogram did not detect any abnormalities.
Our pharmacological options to treat PK’s psychosis became increasingly limited. In late June 2019, we elected to
use quetiapine to target schizophrenia. We favored quetiapine
over aripiprazole because of the continued concern over
aripiprazole’s potential to cause akathisia and exacerbate excitatory catatonia. From late June to August 2019, quetiapine
was titrated to a total daily dose of 800 mg. But he failed to
demonstrate any response to quetiapine, either.
Volume 30 • Number 4 • July/August 2022
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As treatment failures continued to accumulate, we elected to
use olanzapine at treatment- refractory doses. We did not utilize
this strategy earlier due because of its mixed level of evidence.
From August through October 2019, olanzapine was titrated to 40 mg nightly. His psychotic symptoms responded
as the olanzapine dose was escalated beyond 20 mg, and by
December 2019, his psychotic symptoms were considerably
ameliorated with only mild auditory hallucinations. Catatonia remained fully resolved.
Over the following year lorazepam was slowly down titrated and discontinued without reemergence of catatonia.
We attempted to reduce the olanzapine to the lowest effective
dose; however, at 20 mg, psychotic symptoms began to reemerge. Olanzapine is therefore currently being continued
at 25 mg nightly as maintenance treatment.
Although PK is improved, we continue to reflect on a salient
and troubling issue in his care—our inability to obtain ECT.
Initially, the local hospital did not pursue ECT for PK because
of his lack of insurance coverage. When we approached the
same hospital again regarding ECT, he was declined for the
same reason. After we identified a second facility with ECT capabilities within our health system, the treatment team declined to pursue ECT. The only remaining option within our
health system for ECT was outpatient ECT. However, the performing physician deemed that PK’s condition was too acute
for outpatient ECT. At that point, we discussed with PK’s
mother the option to recontact the treatment team from the
second facility, but she declined. We highlight that improved
access to ECT may have expedited PK’s recovery.*

QUESTIONS TO THE CONSULTANTS
− How do you think about “treatment resistance” when
applied to individuals with schizophrenia? (Dr. Cotes)
− How would you contextualize this young man’s antipsychotic “treatment resistance” within the existing literature on this topic? (Dr. Cotes)
− For this young man, a retrial of high-dose olanzapine was
chosen after he suffered clozapine-induced myocarditis.
How do you approach treatment resistance, including in a
patient with clozapine-induced myocarditis? What options would you consider for this patient? (Dr. Cotes)
− What is the best pharmacological approach for patients
with concurrent catatonia and psychosis? (Dr. Beach)
− When would you consider ECT? (Dr. Beach)
− What would you recommend in managing the young
man in this presentation regarding these concurrent
problems? What patient factors would you consider
most relevant in developing a treatment plan and appropriate treatment setting? (Dr. Beach)
Robert Cotes, MD
HOW DO YOU THINK ABOUT “TREATMENT RESISTANCE” WHEN APPLIED TO
INDIVIDUALS WITH SCHIZOPHRENIA? The term treatment resistance
* The case history was prepared by Mohan Gautam, DO, MS, and Mauran
Sivananthan, DO.
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can erroneously evoke a sense of therapeutic nihilism or can
mistakenly imply that a person is “resistant” or unwilling to
participate in treatment. Despite the potentially misleading
nomenclature, treatment-resistant schizophrenia (TRS) is a
valuable clinical and research construct that can be utilized,
in part, to determine who may benefit from a clozapine trial.
The incidence of TRS varies depending on the population
studied and the definition used, but it is commonly cited that
20%–30% of people with schizophrenia have TRS.1 That
number may actually be higher. In a meta-analysis including
over 6000 patients looking at various cutoff points with the
Positive and Negative Syndrome Scale (PANSS) and Brief Psychiatric Rating Scale (BPRS), the nonresponse rate for treatment with a single non-clozapine antipsychotic was 19.8%
for ≤0% change in PANSS/BPRS score, 43% for <25% change
in PANSS/BPRS score, and 67% for <50% change in PANSS/
BPRS score.2 After years of various definitions applied in the literature, the Treatment Response and Resistance in Psychosis
(TRRIP) Working Group published a consensus definition
for TRS in 2017. Highlights of the minimum TRRIP TRS requirement include moderate clinical and functional symptoms as measured by a standardized rating scale, ≥12 weeks
total duration of impairment, and ≥2 past adequate antipsychotic trials at a therapeutic dosage where a person has been
adherent for at least six weeks.3
Clozapine is the only medication that is Food and Drug
Administration–approved for TRS, and the recently published American Psychiatric Association Practice Guidelines
for the Treatment of Patients with Schizophrenia recommend
that patients with TRS be treated with clozapine.4 Response
rates for people with TRS are 0% for typical antipsychotics,
10% for atypical antipsychotics, and 40%–60% for clozapine.5,6 Clozapine is generally underutilized in the United States,
and there is ample evidence of racial and ethnic disparities in
clozapine-prescribing practices.7,8 Prescriber reluctance is a major
barrier to clozapine’s use. In a survey of 143 U.S. psychiatrists,
38% would rather combine two antipsychotics than use clozapine, and only 45% would use clozapine after two or fewer antipsychotic failures.9 Efforts should be made to promote clozapine
use as soon as possible without unnecessary antipsychotic trials.
In a survey of 86 individuals on clozapine in the southeastern
United States, the median number of self-reported antipsychotic
trials prior to clozapine was four.10 Some data suggest pursuing a trial of clozapine after failure of only one antipsychotic
medication.11 Delays in initiating clozapine use can result in
poorer response,12 and prescribers should make every possible attempt to reduce the duration of treatment resistance.13
It is important to differentiate TRS from pseudo-resistance,
where the treatment is inadequate due to an incorrect diagnosis,
kinetic issues, medication nonadherence, or confounding psychiatric or medical comorbidities.14 Remembering the 5 Cs for
TRS may be helpful: (1) correct diagnosis, (2) addressing comorbid conditions, (3) assessing compliance, (4) obtaining concentrations of antipsychotics, and (5) understanding continuous
psychosocial stressors.15 For many individuals, TRS may be
www.harvardreviewofpsychiatry.org
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present from the initial onset of psychosis, but for some, it may
develop later in the illness.16
The pathophysiology of schizophrenia, in general, and the
pathophysiology of TRS, in particular, are not completely understood. Although biological differences may exist between
people with TRS and people with treatment-responsive
schizophrenia, no biomarkers, to date, are clinically available
that allow clinicians to predict who is a clozapine candidate.17
Current biological hypotheses about TRS include dopamine
suprasensitivity, glutamate dysregulation, inflammation and oxidative stress, and hyperdopaminergic and normodopaminergic
subtypes.18 Complicating the matter is a degree of both biological
and clinical heterogeneity within schizophrenia that likely extends
to TRS.19
HOW

WOULD YOU CONTEXTUALIZE THIS YOUNG MAN’S ANTIPSY-

CHOTIC “TREATMENT RESISTANCE” WITHIN THE EXISTING LITERATURE
ON THIS TOPIC?

Prior to the clozapine trial, the patient was exposed to two different antipsychotics on three separate occasions: (1) risperidone 0.5 mg twice per day, discontinued due
to potentially worsening catatonia, (2) olanzapine titrated to
20 mg, six weeks in duration, discontinued due to lack of efficacy, and (3) retrial of risperidone, titrated to 4 mg, three
months in duration, which was discontinued due to dystonia.
Obtaining therapeutic drug monitoring may be useful before an
antipsychotic trial is deemed a failure—specifically for olanzapine
in this situation. Jointly, the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force
of the Arbeitsgemeinschaft fur Neuropsychopharmakologie und
Pharmakopsychiatrie “strongly recommends” the use of therapeutic drug monitoring for olanzapine (therapeutic blood level
range, 20–80 ng/mL) for a variety of situations, including when
usual therapeutic doses fail to produce a clinical response.20
Additionally, for this patient, his smoking status was unknown.
Aryl hydrocarbons produced from cigarette smoking are strong
inducers of CYP1A2 and can lead to clinically relevant decreases
in olanzapine levels.21
Psychiatric and medical comorbidities are more common
among individuals with TRS than in those without TRS.22
The diagnoses of both autism spectrum disorder (ASD) and
catatonia can certainly complicate and delay the diagnosis
of TRS. The prevalence of ASD in individuals diagnosed with
psychosis exceeds what would be expected in the general population.23 Evidence, though limited, suggests individuals with
ASD who do not respond to other antipsychotics for disruptive behavior may benefit from a clozapine trial.24 The ongoing symptoms of catatonia likely narrowed the list of available antipsychotic medications and, in many scenarios, could
lead to a delayed diagnosis. Regarding catatonia, clinicians
would think of mood disorders perhaps being more common
causes of catatonia than psychotic disorders. However, catatonia can be a feature of schizophrenia without a misdiagnosis. In a meta-analysis examining the prevalence of catatonia,
33 studies found the prevalence of catatonia among individuals diagnosed with schizophrenia to be 9.8%.25
264
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FOR THIS

YOUNG MAN, A RETRIAL OF HIGH-DOSE OLANZAPINE WAS

CHOSEN AFTER HE SUFFERED CLOZAPINE-INDUCED MYOCARDITIS.

HOW

DO YOU APPROACH TREATMENT RESISTANCE, INCLUDING IN A

PATIENT WITH CLOZAPINE-INDUCED MYOCARDITIS?

WHAT OPTIONS
The patient’s treatment
team should be commended for pursing a trial of clozapine
when they did, but unfortunately, the patient developed symptoms concerning for clozapine-induced myocarditis (CIM). This
potentially life-threatening, adverse effect of clozapine has received increased attention in recent years. A systematic review
and meta-analysis found that 6 per 1000 people exposed to clozapine developed CIM, with rates higher in Australia.26 However, a recent U.S. study (with a smaller sample size) found rates
of presumptive myocarditis in 5.3% of first-time starts on clozapine.27 The mean time until onset for myocarditis due to clozapine is 17 days, with 82% occurring between days 14 and 21.28
Risk factors for CIM include older age, co-prescription of sodium valproate, and possibly more rapid clozapine titrations.29
Ronaldson and colleagues28 have proposed a myocarditis
screening protocol that includes baseline echocardiogram,
troponin I/T, and C-reactive protein (CRP). Troponin I/T
and CRP are repeated on days 7, 14, 21, and 28 of treatment.
Elevation of troponin beyond twice the upper limit of normal
or CRP elevation above 100 mg/L is sensitive and specific for
myocarditis, and the authors recommend stopping clozapine.
Myocarditis screening protocols are typically used for the first
six to eight weeks after clozapine initiation, and baseline
echocardiograms are uncommon in the United States. Currently, the American Psychiatric Association schizophrenia
guidelines do not call for mandatory screening labs for
clozapine-induced myocarditis,4 but this practice has been
more common clinically. Cardiac MRI, showing edema and
late gadolinium enhancement, is often one of the best tests
to evaluate for clozapine-induced myocarditis,30 but the investigation was not conducted in this case and can be difficult
to obtain in the acute setting.
For patients who have developed CIM, the therapeutic options are often limited. Prior antipsychotic trials should be reviewed to determine what, if any effect, the other medications
have had. Other non-clozapine antipsychotics are often unlikely to be helpful if the patient does have TRS. Although
several studies have reported the successful use of high-dose
olanzapine (>20 mg/day) for TRS,31,32 this strategy is generally inferior to clozapine when the two are specifically compared.33 PK, the patient in the present case, was fortunate to
have a response to high-dose olanzapine. Additionally, details
around the myocarditis should be reviewed to determine how
convincing the case of myocarditis was. Per the Ronaldson
protocol,28 troponin elevation twice the upper limit of normal
is sufficient, but there are other causes of elevated troponin,
such as physical exercise, which generally peaks after the first
four hours.34,35 In this case, the magnitude of the CRP increase was not quantified; it was noted only to be elevated.
A known history of CIM is not an absolute contraindication to rechallenge with clozapine, and can be pursued with

WOULD YOU CONSIDER FOR THIS PATIENT?
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caution, monitoring, and a detailed risk/benefit conversation with the patient (and support system, if applicable).
In a review of published case reports, rechallenge after
myocarditis was successful in 11/17 cases.36 Some keys to
successful re-titration potentially include a very slow titration, careful (and possibly daily) vital sign monitoring,
and co-management with cardiology. Some authors recommend delaying a clozapine retrial until six months after the
initial CIM episode.37
Scott Beach, MD
WHAT IS THE BEST PHARMACOLOGICAL APPROACH FOR PATIENTS WITH
CONCURRENT CATATONIA AND PSYCHOSIS? Catatonia is best thought
of as a syndrome—a constellation of symptoms that, like delirium, can occur in the setting of various psychiatric and
neuromedical insults, particularly in patients with a preexisting vulnerability. Regardless of the underlying diagnosis, catatonia often occurs in the presence of psychosis. The psychosis may exist as a symptom of a psychiatric illness such as
schizophrenia, bipolar disorder, or unipolar depression, or
it may occur in the setting of delirium or substance use. Common psychotic experiences in catatonia include persecutory
and nihilistic delusions. Cotard’s syndrome, for example, in
which patients believe that they are dead or dying, rotting
from the inside, or missing vital organs, has a high overlap
with catatonia. Following an episode of catatonia, many patients will have psychotic explanations for some of their catatonic features. For example, they may state that the voice of
Satan was telling them not to move or speak, or that they felt
as though they were being controlled by some outside force
and did not have control over their limbs.
Despite the common overlap, the management of cooccurring psychosis and catatonia represents a major treatment challenge. One of the guiding principles of managing
catatonia is that, as with delirium, the underlying cause must
be treated in order to prevent recurrence. It is therefore essential to consider the context in which catatonia is occurring
when choosing a treatment approach. Other important factors to consider include potential medical comorbidities that
may convey risk with certain management strategies, the duration of catatonia (with longer durations typically conveying
a lower treatment response), the presence of malignant features, prior medications trials and past responses, and the
current setting.
As the first-line treatment for catatonia, benzodiazepines
are unlikely to mitigate psychosis and may, in fact, unmask
psychosis by temporarily treating the catatonia. It is not uncommon, for example, for an immobile, mute patient with
catatonia to suddenly become aggressive and with obvious
psychosis following a lorazepam challenge. Similarly, amantadine, which is sometimes used as a second- or third-line
agent in managing catatonia, has dopamine agonist properties, which can directly worsen psychosis. Conversely, antipsychotic agents have the potential to induce or worsen catatonia, sometimes leading to the development of malignant
Harvard Review of Psychiatry

features, including fever, autonomic instability, and leadpipe rigidity, and must therefore be used very cautiously
in catatonia.
In approaching the management of a patient with catatonia and psychosis, although benzodiazepines have the potential to unmask psychosis, they still represent the best initial
course of action. Benzodiazepines are thought to work by
causing a reduction in orbitofrontal cortex and ventromedial
prefrontal cortex hyperactivation, leading to a regularization
of the orbitofrontal cortex activity, as well as GABA-A interneuron agonism in the striatum, ventral tegmental area/substantia
nigra, and thalamus.38 Lorazepam is the preferred benzodiazepine because of its preference for GABA-A receptors, combined
with its availability in a variety of preparations.39 Generally, a
2 mg lorazepam challenge is used to confirm the diagnosis of
catatonia and assess the likely response to benzodiazepines.
For patients in hospital settings, intravenous lorazepam is
always preferred, as it is fast acting and, despite having
the same T1/2 as other forms, has a longer effective length
of action. Intramuscular preparations are generally avoided
for repeat injections, as they may worsen the catatonia fear
response and may also create challenges in determining
whether malignant features are present by elevating the creatinine kinase. On an outpatient basis, sublingual lorazepam is
preferred over the oral form, as it appears to have greater effect. Dosing of lorazepam is typically started at 2 mg every 6–
8 hours, though higher doses up to 24 mg daily are sometimes
needed. Importantly, lorazepam may need to be dosed more
frequently in patients with refractory catatonia and ideally
should be dosed around the clock in order to prevent worsening overnight in the setting of a long interval between doses.
Benzodiazepines should not be held for sedation in the setting
of catatonia.
WHEN WOULD YOU CONSIDER ECT? When psychosis is present,
attempts should be made to pursue electroconvulsive therapy
as early as possible. Some evidence suggests that benzodiazepines may be less effective for catatonia in the setting of psychosis, particularly if the psychosis is the result of an underlying schizophrenia spectrum disorder, though this teaching has
been called into question in recent years.40 Guidelines regarding ECT vary significantly by state, and ECT may not be a
feasible strategy in many jurisdictions. In some states, a court
order is required, which can be a prolonged process. Depending on the presence of medical comorbidities, individual ECT
services may also be reluctant to pursue treatment of specific
patients. Nonetheless, ECT represents the best chance for improvement in comorbid catatonia and psychosis, with improvements seen in up to 90% of patients, including up to
60% of those who fail benzodiazepines.41 The exact mechanism of ECT in catatonia remains unclear, but possible effects
include increased blood flow to orbitofrontal and parietal
cortices, increased GABA activity and GABA receptor expression, increased dopamine release and modulation of dopamine receptors, and possible immunomodulatory effects.42
www.harvardreviewofpsychiatry.org
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If ECT is an option, consent must be obtained. Since most
catatonic patients will be unable to give consent for the procedure, a proxy consent is typically used. Typically, at least 6
sessions of ECT are required to treat catatonia, with most patients requiring 9–12 sessions. Bitemporal placement with brief
pulse is most commonly used, and patients are typically treated
at least three times weekly and sometimes daily. Some evidence
suggests that a combination of ECT and low-dose lorazepam
may be particularly efficacious.43 If the ongoing use of lorazepam presents concerns about the seizure threshold, flumazenil
and augmentation with hyperventilation and caffeine can be
considered. For patients who improve with ECT, maintenance
treatments are often required to prevent relapse.
WHAT WOULD YOU RECOMMEND IN MANAGING THE YOUNG MAN IN
THIS PRESENTATION REGARDING THESE CONCURRENT PROBLEMS?

WHAT

PATIENT FACTORS WOULD YOU CONSIDER MOST RELEVANT IN

successfully used to treat catatonia in any reports—which would
be consistent with what happened in this case. Olanzapine
has also been reported as successful in seven cases and may
be a better option, given its relatively lower potency.44 In this
case, the patient’s catatonia appears to have eventually responded
well to high-dose olanzapine, which also successfully treated
his psychosis.
Of all of the antipsychotics, aripiprazole has actually
been reported to have been successful in the largest number
of cases (9) and may be a great choice because of its partialagonist activity at the D2 receptor, which may lower the
risk of worsening catatonia.7 While the concern about inducing akathisia is certainly valid, the potential benefits
of aripiprazole over other antipsychotic agents may outweigh this risk. Furthermore, aripiprazole has a relatively
wide dose range, which may be advantageous if high doses
are needed.

DEVELOPING A TREATMENT PLAN AND DETERMINING AN APPROPRIATE
TREATMENT SETTING?

In this case, I would want to understand
better what the ECT physician felt were the significant risks
associated with treatment. If these risks could be mitigated
in some way, ECT has the potential to be a life-altering treatment for this patient.
If the catatonia does not respond to benzodiazepines and
ECT is not an option, several other medications have been used
for catatonia. NMDA antagonists such as memantine and
amantadine would typically be the next step in the treatment algorithm, though they would not specifically target the underlying psychosis.44 Another option would be to use an antiepileptic drug, such as valproate or carbamazepine. This option
may be a particularly attractive if the catatonia and psychosis
are thought to be secondary to an underlying bipolar disorder.
As in this case, antipsychotic agents are often considered
for the management of co-occurring catatonia and psychosis.
Case reports of success in treating catatonia exist for many
second-generation antipsychotics.45 Atypical antipsychotics
are hypothesized to treat catatonia via effects on serotonin receptors, which may lead to an increase in dopamine in the
prefrontal cortex.46 In general, we recommend using lowpotency agents to minimize the risk of worsening catatonia or
inducing a malignant catatonia. Additionally, antipsychotics
should always be given directly in combination with benzodiazepines in order to further minimize the risk.
Risperidone has been reported to have been successful in
treating seven cases of catatonia, almost all of whom had an
underlying schizophrenia.44 As a high-potency agent, however, it may not be the ideal first choice for an antipsychotic
and should be used with extreme caution—and always combined directly with benzodiazepines. In this case, the case
history posits that risperidone may have led to worsening
of catatonia when it was first used. Clozapine has been used
in a handful of cases but seems to be most effective when catatonia occurs in the setting of clozapine withdrawal. In this
case, clozapine had to be stopped because of the development of myocarditis. Interestingly, quetiapine has never been
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FINAL QUESTIONS: How would you manage this young
man going forward? Do you recommend certain monitoring parameters or referrals? Do you foresee the development of other
complications? (Drs. Beach and Cotes)
Scott Beach, MD
The patient’s catatonia has remained in remission following
successful treatment. Given the severity and the duration of
the catatonia, PK is definitely someone for whom I would
consider maintenance benzodiazepine treatment as a way to
mitigate the risk of recurrence. While no guidelines exist for
maintenance therapy, it is an important consideration in patients who have prolonged episodes of catatonia that are refractory to treatment. Two of the biggest risk factors for catatonia recurrence are the rapid taper of benzodiazepines
and repeated episodes of catatonia, neither of which applies
in this case. Nonetheless, the patient’s catatonia was clearly
refractory to multiple treatments, and his psychotic disorder
appears to be fairly brittle—both of which may increase the risk
for recurrence. Furthermore, his underlying autism spectrum
disorder conveys a high-risk for catatonia, with many patients
experiencing recurrent episodes of catatonia throughout their
lives. Given these factors, PK may be someone who would benefit from continued treatment with lorazepam 1–2 mg daily.
While some prescribers worry about the risk of long-term benzodiazepine usage, including dependence and cognitive concerns, most patients treated with maintenance benzodiazepines
for catatonia do not develop significant problems. It is also
worth noting that subsequent episodes of catatonia may prove
even more challenging to treat, making a more compelling argument for prevention. It is even possible that catatonia, like
epilepsy and mood disorders, could create a kindling effect,
whereby each subsequent episode increases the risk of further
future episodes and the interval in between episodes becomes
shorter. The typical course of periodic or recurrent idiopathic
catatonia would seem to fit such a hypothesis.46,47
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In terms of the antipsychotic medication, olanzapine appears to be a successful strategy for mitigating his psychosis
and should be continued. The case points out that an attempt
to taper the dose even slightly led to reemergence of psychosis.
As noted above, the fact that olanzapine is a low-potency
agent means that it conveys lower risk for worsening catatonia than some other agents may. Were olanzapine to cease being effective at some point, or intolerable side effects to develop, it would be worth reconsidering a trial of aripiprazole,
given the advantages outlined above.
The Bush-Francis Catatonia Rating Scale is an excellent
tool for monitoring for reemergence of catatonia and should
be administered at regular intervals during psychiatric followup. Given that patients with recurrent catatonia most commonly display the same symptoms with each episode, it
would be reasonable to pay particular attention to early
symptoms such as mutism, withdrawal, and immobility in
PK’s case. Psychiatrists should keep in mind that all of the
symptoms of catatonia exist on a spectrum; presentations
may be quite subtle early on. For example, whereas many
psychiatrists think of mutism only as a marked reduction in,
or the complete absence of, speech, other forms of mutism include hypophonia, reduced speech, and unusual speech patterns such as one where the volume of the voice decreases toward the end of each sentence or clause. Should symptoms reemerge, early treatment with benzodiazepines may be useful
in mitigating symptoms. Sublingual, rather than oral, lorazepam may be helpful if available, and outpatient treaters might
consider an increased frequency of dosing, such as every six
hours if needed.
Should PK become catatonic again, it will be important to
monitor him for complications, particularly if his catatonia is
prolonged, as it was during his first episode. Simple catatonia
can lead to a host of medical sequelae, including aspiration,
dehydration, pneumonia, deep vein thrombosis, pulmonary
emboli, and urinary retention. Were PK to develop malignant
features of catatonia, potential sequelae include acute renal
failure, acute respiratory distress syndrome, cardiac arrest,
disseminated intravascular coagulation, seizures, rhabdomyolysis, respiratory arrest, and death.
Robert Cotes, MD
I would be curious to learn more information about the nature of the current reemergence of symptoms and the level
of functional impairment. I would also be interested to learn
what is most bothersome for the patient and to develop the
treatment plan around his priorities. It would be helpful to
quantify and track symptoms with a brief rating scale, like
the Clinician-Rated Dimensions of Psychosis Symptom Severity scale found in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders,48 or the Clinical Global
Impression Scale.49 Ongoing monitoring for catatonia with
the Bush-Francis Catatonia Rating Scale would also be warranted. I would have a low threshold to restart lorazepam
should the symptoms of catatonia appear again.
Harvard Review of Psychiatry

Having the patient remain on olanzapine and titrating the
dose to symptom improvement in the short-term is a reasonable strategy. However, olanzapine has one of the most significant cardiometabolic liabilities of any antipsychotic,50 and
the effect may be more pronounced in young people.51 It
would be essential to monitor for weight gain, diabetes, and
hyperlipidemia per the American Psychiatric Association/
American Diabetes Association Consensus guidelines.52 In
addition to counseling about diet and exercise, augmentation
with a compound that might help to mitigate weight gain,
such as metformin, may be a consideration. In a meta-analysis
including four studies and 105 patients on olanzapine and metformin (doses ranging from 750–1750 mg), the weighted mean
difference for body weight was 5 kg lower for metformin versus
placebo.53 If the positive symptoms remain problematic and
functionally impairing, a rechallenge with clozapine is a possibility even after myocarditis, but the same cardiometabolic
issues remain.
Consideration of aripiprazole, which would have a more
benign cardiometabolic profile,50 may be an option rather
than olanzapine. Available evidence suggests that switching
to aripiprazole from other antipsychotics is feasible from an
efficacy standpoint and may reduce cardiometabolic burden.54 In a meta-analysis looking at 22 randomized, controlled trials, no difference in psychotic worsening was found
when switching to aripiprazole versus switching to another
antipsychotic, although switching to aripiprazole was associated with greater risk of study discontinuation because of the
lack of efficacy.55 In a population-based cohort study from
the United Kingdom that involved 1643 people starting aripiprazole who had previously been taking another antipsychotic, the treatment failure incident rate was 13.1 per 100
person-years, which did not differ significantly from those
who were switched to a different antipsychotic.56 Taken together, these studies suggest that transition to aripiprazole is
possible but that clinical vigilance is necessary. Furthermore,
in a patient with a recent history of catatonia, aripiprazole
may be a reasonable option and may be less likely than other
high-potency antipsychotic agents to worsen catatonia.44
Finally, I would make sure to optimize psychosocial interventions, which could include cognitive-behavioral therapy for psychosis, supported employment, peer support, and family-based
interventions. With symptoms beginning in January 2019, the
patient may, in some areas, still be eligible for coordinated
specialty care services for first-episode psychosis, which has
been shown to improve outcomes in multiple domains.57,58
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